# Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)

> **NCT03525418** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Longeveron Inc.** · enrollment: 10 (actual)

## Conditions studied

- HLHS

## Interventions

- **BIOLOGICAL:** Longeveron Mesenchymal Stem Cells

## Key facts

- **NCT ID:** NCT03525418
- **Lead sponsor:** Longeveron Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-21
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03525418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03525418, "Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03525418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*